All translations

Enter a message name below to show all available translations.

Found 2 translations.

Name	Current message text
^h English (en)	One placebo-controlled, double-blind study was carried out at 18 different sites in Korea and 12 in Taiwan. Patients were above 20 and had type 2 diabetes for atlas 12 weeks. They were given an 8-week period to clear their systems of all other drugs (besides metformin). Patients received either 50 mg ipragliflozin or a placebo. The drugs were identical in all physical forms. The patients were prohibited from using any other anti diabetic drugs, other than metformin. The study ran for 24 weeks along with a 4-week follow-up period. The standard deviation in [[Glycated hemoglobin\|hemoglobin A<sub>1c</sub>]] were −0.94% and −0.47% in the ipragliflozin and placebo groups, respectively (between-group difference −0.46%, [[p-value\|''p'']] <0.001). The changes in fasting plasma glucose and bodyweight were also significantly greater in the ipragliflozin group, with between-group differences of −14.1 mg/dL and −1.24 kg, respectively (both ''p'' <0.001). The most common adverse events that appeared were [[Upper respiratory tract infection\|upper respiratory infection]]s and [[urinary tract infection]]s. From this it was concluded that ipragliflozin is both efficacious as well as safe.
^h Japanese (ja)	プラセボ対照二重盲検試験が韓国の18ヵ所と台湾の12ヵ所で行われた。対象は20歳以上で2型糖尿病を12週間以上患っている患者であった。8週間の休薬期間を設け、メトホルミン以外の薬物をすべて除去した。患者は50mgのイプラグリフロジンとプラセボのいずれかを投与された。薬物は物理的な形はすべて同じであった。患者はメトホルミン以外の抗糖尿病薬の使用を禁止された。試験は4週間の追跡期間とともに24週間行われた。 [[Glycated hemoglobin/ja\|ヘモグロビンA<sub>1c</sub>]]の標準偏差はイプラグリフロジン群で-0.94％、プラセボ群で-0.47％であった（群間差-0.46％、[[p-value/ja\|''p'']]<0.001）。空腹時血糖値および体重の変化もイプラグリフロジン群で有意に大きく、群間差はそれぞれ-14.1 mg/dLおよび-1.24 kgであった（いずれも''p''<0.001）。最も多くみられた有害事象は[[Upper respiratory tract infection/ja\|上気道感染症]]と[[urinary tract infection/ja\|尿路感染症]]であった。以上より、イプラグリフロジンは有効であると同時に安全であると結論された。